Skip to main content

Health condition · Clinically reviewed

Chondrosarcoma, the cartilage bone cancer that surgery leads.

A cartilage-producing bone tumour usually treated at a UK sarcoma centre with wide surgical resection, limb-salvage reconstruction and, for skull-base disease, proton beam therapy.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE, BSG (British Sarcoma Group), ESMO and peer-reviewed sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK sarcoma pathways, IDH1 inhibitor developments and proton beam therapy for skull-base disease.

Key facts

Chondrosarcoma at a glance.

The essentials, in plain English - what chondrosarcoma is, who it affects, and how UK sarcoma centres treat it today.

  • What it is

    A malignant cartilage-producing bone tumour, the second most common primary bone cancer after osteosarcoma.

  • Who it affects

    Typically adults aged 40 to 60, with the pelvis, femur and humerus the most common sites.

  • Behaviour

    Usually slow-growing with a long history of pain, but higher-grade and dedifferentiated forms behave far more aggressively.

  • Subtypes

    Conventional (about 85%), dedifferentiated, mesenchymal, clear cell, myxoid and extraskeletal variants.

  • Mainstay of care

    Surgery. Chondrosarcoma is largely resistant to chemotherapy and conventional radiotherapy.

  • Molecular clue

    IDH1 and IDH2 mutations are found in 50 to 80% of conventional chondrosarcomas and open the door to targeted therapy.

Why this guide matters

A sarcoma-centre problem, not a local one.

The three points below shape every decision on this page - subtype matters, surgery leads, and the biopsy belongs at a designated centre.

  • Subtype drives everything

    Conventional, dedifferentiated, mesenchymal, clear cell and myxoid variants behave very differently - the plan follows the pathology.

  • Surgery leads

    Chondrosarcoma is largely chemo-resistant and radio-resistant, so wide en bloc resection at a sarcoma centre is the single most important step.

  • Biopsy at the right place

    Core biopsy tract must lie within the future resection field - a biopsy done outside a sarcoma centre can compromise the whole operation.

Subtypes

The chondrosarcoma family.

Behaviour, prognosis and treatment vary sharply between subtypes - the histology sets the ceiling and the floor.

  • Conventional (about 85%)

    Graded 1 to 3. Grade 1 (now often called atypical cartilaginous tumour, ACT) is low-risk in the limbs; grades 2 and 3 behave more aggressively.

  • Dedifferentiated

    A dual histology of low-grade cartilage and high-grade sarcoma - highly aggressive with a very poor prognosis and often systemic treatment.

  • Mesenchymal

    Affects younger adults, has a predilection for the head, neck and jaw, and is chemo-sensitive - treatment includes surgery, chemotherapy and radiotherapy.

  • Clear cell

    Rare, low- to intermediate-grade lesion arising in the epiphysis of long bones - managed with wide surgical resection.

  • Myxoid chondrosarcoma

    A distinct entity with prominent myxoid matrix - can behave indolently but has a tendency to recur.

  • Extraskeletal chondrosarcoma

    Arises in soft tissues rather than bone; managed within the soft-tissue sarcoma pathway.

How the diagnosis is made

From first X-ray to a sarcoma MDT plan.

The steps a UK sarcoma pathway will normally follow, in order - so you know what to expect and why every step matters.

  1. 01

    Imaging

    Plain X-ray

    A lytic, expansile lesion with endosteal scalloping and ring-or-arc calcification is the classic first sign.

  2. 02

    Imaging

    MRI (gold standard)

    Defines intramedullary extent, soft-tissue mass and involvement of neurovascular structures for surgical planning.

  3. 03

    Imaging

    CT of the lesion

    Characterises cortical destruction and the pattern of calcification when radiographs are ambiguous.

  4. 04

    Confirming

    Staging CT chest and whole body

    CT chest for pulmonary metastases; whole-body imaging for skeletal spread in higher-grade disease.

  5. 05

    Confirming

    Specialist-centre core biopsy

    CT-guided core biopsy at a designated sarcoma centre only, along a planned tract the future resection can excise.

  6. 06

    Confirming

    IDH1 and IDH2 mutation testing

    Molecular profiling supports diagnosis in equivocal cases and identifies eligibility for IDH inhibitor trials.

  7. 07

    MDT

    Sarcoma MDT review

    A designated UK sarcoma centre MDT (RNOH Stanmore, Birmingham ROH, The Christie, Royal Marsden, Newcastle, Nottingham, Sheffield, Bristol, Leeds, Cambridge, Edinburgh, Glasgow or Cardiff) agrees the plan.

Typical timeline: imaging to sarcoma-MDT plan within a few weeks at a designated centre.

Symptoms

What chondrosarcoma actually feels like.

Slow-onset deep bone pain in a middle-aged adult, often around the pelvis, thigh or shoulder - and the features that mean it is time to escalate quickly.

  • Progressive bone pain

    A deep, gnawing pain that worsens over months and, characteristically, disturbs sleep at night.

  • Localised swelling

    A firm, deep swelling around the pelvis, thigh, shoulder or ribs that grows slowly over time.

  • Long history

    Symptoms often present for many months or years, particularly in low-grade conventional disease.

  • Pathological fracture

    A break through a weakened lesion after minor trauma can be the first presentation of a chondrosarcoma.

  • Neurological signs

    Sciatica-like pain, weakness or numbness when a pelvic or spinal lesion presses on nerve roots.

  • Skull-base symptoms

    Headache, double vision or cranial nerve palsies when a chondrosarcoma arises at the skull base.

  • Restricted joint movement

    Stiffness or a mechanical block from a juxta-articular lesion around the hip, shoulder or knee.

  • Red flag - rapid growth

    Rapid enlargement, systemic symptoms or a soft-tissue mass suggests high-grade or dedifferentiated disease and needs urgent sarcoma referral.

Treatment

How chondrosarcoma is treated in the UK.

Wide surgical resection at a sarcoma centre, with limb-salvage reconstruction, proton beam therapy for skull-base disease and chemotherapy or IDH1 targeted therapy for selected subtypes.

  • Wide surgical resection

    The cornerstone of care - en bloc excision with clear margins by a specialist orthopaedic oncology team.

  • Limb-salvage endoprosthesis

    Custom endoprosthetic reconstruction after resection of the femur, tibia or humerus preserves function - see our guide to limb-salvage endoprostheses.

  • Intralesional curettage

    For selected low-risk atypical cartilaginous tumours in the limbs, extended curettage with phenol, cryotherapy or PMMA cement.

  • Pelvic and spinal resection

    Highly specialist en bloc resection with pelvic reconstruction or selective hemipelvectomy for pelvic primaries.

  • Proton beam therapy

    The mainstay of skull-base chondrosarcoma, delivering 70+ Gy while sparing brainstem, optic apparatus and cochlea.

  • IMRT or photon radiotherapy

    Considered for close margins, unresectable pelvic disease and palliation when protons are not appropriate.

  • Chemotherapy (selected subtypes)

    Doxorubicin, ifosfamide and cisplatin regimens for mesenchymal and dedifferentiated chondrosarcoma - limited role in conventional disease.

  • IDH1 targeted therapy

    Ivosidenib (FDA-approved for IDH1-mutant chondrosarcoma in 2024) and emerging agents such as vorasidenib within clinical trials.

What this guide is based on

The sources behind every claim on this page.

UK national guidance, European society standards and patient-charity resources, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your sarcoma-centre team knows your imaging, pathology and history and can tell you which parts apply to you. If in doubt, get seen.

  • NICE. Suspected cancer: recognition and referral (NG12) - sarcoma pathway.

  • British Sarcoma Group (BSG). Guidelines for the management of bone sarcomas.

  • ESMO / EURACAN / GENTURIS Clinical Practice Guidelines. Bone sarcomas: diagnosis, treatment and follow-up.

  • Royal College of Radiologists. Proton beam therapy service specification (skull-base chondrosarcoma).

  • Sarcoma UK and Bone Cancer Research Trust patient information resources.

Red flags

When chondrosarcoma needs urgent attention.

These are the presentations that shift care from watchful waiting to an urgent sarcoma-centre referral.

  • Rest and night pain

    Deep bone pain that wakes you at night is a classic sarcoma red flag and warrants urgent imaging.

  • Pathological fracture

    A fracture through a lytic bone lesion needs referral to a sarcoma unit before any definitive surgery.

  • Rapidly enlarging soft-tissue mass

    Sudden change in a long-standing swelling can signal dedifferentiation and demands urgent MDT review.

  • Dedifferentiated chondrosarcoma

    A dual-histology aggressive variant with poor prognosis - always managed at a specialist sarcoma centre.

  • Cranial nerve or visual symptoms

    New diplopia, facial numbness or hearing loss in the context of a skull-base lesion needs urgent neuro-oncology input.

  • Multiple hereditary exostoses

    EXT1 / EXT2 osteochondromas carry a lifetime risk of secondary chondrosarcoma - any new pain or growth in adulthood needs review.

  • Ollier or Maffucci syndrome

    Multiple enchondromas (with haemangiomas in Maffucci) carry a substantial risk of malignant transformation - lifelong surveillance is essential.

  • Post-radiation sarcoma

    A new bone lesion within a prior radiotherapy field should be considered sarcoma until proven otherwise.

  • Unplanned excision elsewhere

    Any lesion resected without a sarcoma-centre plan needs urgent re-referral - inappropriate surgery worsens outcomes.

Living with it

A treatable cancer, with long horizons.

Chondrosarcoma outcomes rest on specialist surgery, structured rehabilitation and long-term surveillance - the four points opposite matter most day to day.

A quiet reminder

Follow-up is part of the treatment.

Scheduled scans and clinic reviews catch late recurrences early - do not let the calendar slip once you feel well.

  1. 01 Team

    A sarcoma centre for life

    Care sits with a designated UK sarcoma MDT. Long-term follow-up, imaging surveillance and any complications are best kept there.

  2. 02 Function

    Rehabilitation matters

    After limb-salvage surgery, physiotherapy and prosthetic follow-up shape long-term function - engage early and stay engaged.

  3. 03 Surveillance

    Late recurrence is real

    Chondrosarcoma can recur years after treatment. Structured imaging follow-up continues for a decade or more, particularly for higher grades.

  4. 04 Support

    Charity support is excellent

    Sarcoma UK and Bone Cancer Research Trust offer specialist nurses, peer networks and practical resources - use them.

Frequently asked

Everything we get asked about chondrosarcoma.

Quick answers on diagnosis, sarcoma-centre surgery, proton beam therapy and IDH1 targeted options.

  • What is chondrosarcoma?

    Chondrosarcoma is a malignant tumour that produces cartilage matrix. It is the second most common primary bone cancer after osteosarcoma and most often affects adults aged 40 to 60. The pelvis, femur and humerus are the commonest sites, and most cases are slow-growing conventional (grade 1 or 2) disease.

  • How is chondrosarcoma diagnosed?

    Diagnosis starts with plain X-ray, followed by MRI as the gold standard for local extent and CT for cortical detail and calcification pattern. Staging uses CT of the chest and whole-body imaging. A CT-guided core biopsy should only be performed at a specialist sarcoma centre, along a tract the future surgical resection can remove.

  • Why is surgery the main treatment?

    Chondrosarcoma is largely resistant to chemotherapy and conventional radiotherapy, so wide surgical resection with clear margins is the mainstay. Limb-salvage with an endoprosthesis preserves function in most extremity cases, and selected low-risk atypical cartilaginous tumours can be treated with extended intralesional curettage.

  • When is radiotherapy used?

    Proton beam therapy is central to the management of skull-base chondrosarcoma, delivering high doses while sparing the brainstem and optic apparatus. IMRT and photon radiotherapy are used for close margins, unresectable pelvic disease and palliation. Mesenchymal and dedifferentiated subtypes may receive radiotherapy alongside surgery.

  • What is dedifferentiated chondrosarcoma?

    A high-grade variant with two histologies side by side - a low-grade cartilage tumour and an aggressive high-grade sarcoma. It behaves very aggressively, has a poor prognosis, and needs an intensive multidisciplinary approach that often includes chemotherapy, wide surgery and radiotherapy.

  • Are there targeted treatments for chondrosarcoma?

    Yes - between 50 and 80% of conventional chondrosarcomas carry IDH1 or IDH2 mutations. Ivosidenib, an IDH1 inhibitor, received US FDA approval for IDH1-mutant chondrosarcoma in 2024, and agents such as vorasidenib are being evaluated. UK patients access these mainly through clinical trials at designated sarcoma centres.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.